Physician profile
Dolly Patel
NPI 1669887972
$717.58
in general payments reported to CMS, 2019-2025
13 companies · $33.55 in 2025
The $33.55 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2021: $105 · 2022: $76.53 · 2023: $303 · 2025: $33.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $319 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $318.74 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $199.98 | 2019 | |
| Glaxosmithkline, LLC. | $148.98 | 2021-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.97 | 2021-2023 | Ofev |
| Astrazeneca Pharmaceuticals LP | $41.57 | 2022-2023 | Tezspire, Fasenra |
| Pulmonx Corporation | $30.70 | 2023 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Regeneron Healthcare Solutions, INC. | $28.46 | 2022-2023 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $27.92 | 2021-2022 | |
| Baxter Healthcare | $27.49 | 2023 | Hillrom - Life 2000 Ventilation System |
| Insmed, INC. | $17.38 | 2025 | Brinsupri |
| Janssen Pharmaceuticals, INC | $15.79 | 2021 | |
| Mylan Specialty L.P. | $12.22 | 2021 | |
| Insulet Corporation | $11.72 | 2021 | |
| Genzyme Corporation | $11.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dolly Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.